Anavex Life Sciences Corp.

AVXL

US0327973006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
4.49 ^USD	+4.18%		+21.02%	-51.77%

May. 09	Transcript : Anavex Life Sciences Corp., Q2 2024 Earnings Call, May 09, 2024
May. 09	Anavex Life Sciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI

Anavex Life Sciences Corp. Appoints Stephan Toutain as Senior Vice President Operations and Claus Van Der Velden to Board of Directors

May 10, 2018 at 07:00 am EDT

Anavex Life Sciences Corp. appointed Anavex as Senior Vice President Operations and Claus van der Velden, PhD was appointed to the Board of Directors.

Latest news about Anavex Life Sciences Corp.

Transcript : Anavex Life Sciences Corp., Q2 2024 Earnings Call, May 09, 2024	May. 09
Anavex Life Sciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 09	CI
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia	Mar. 18	CI
Transcript : Anavex Life Sciences Corp., Q1 2024 Earnings Call, Feb 07, 2024	Feb. 07
Anavex Life Sciences Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 07	CI
North American Morning Briefing : Stock Futures -2-	Feb. 07	DJ
Anavex Life Sciences Initiates Phase 2 Trial of Schizophrenia Therapy	Jan. 17	MT
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia	Jan. 16	CI
Transcript : Anavex Life Sciences Corp. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM	Jan. 11
Anavex Life Sciences Corp. Provides an Update on Rett Syndrome Program	Jan. 02	CI
Anavex Life Sciences Corp. Announces First Entire Clinical Gene Pathway Data of Anavex®2-73 from Avatar Study in Patients with Rett Syndrome	Dec. 20	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Dec. 19	MT
Sector Update: Health Care Stocks Gain in Afternoon Trading	Dec. 19	MT
Anavex Life Sciences Shares Rise on European Approval of Marketing Application for Oral Blarcamesine in Alzheimer's	Dec. 19	MT
Anavex Life Sciences Corp. Receives Agreement from the Committee for Medicinal Products for Human Use for the Submission of A Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease	Dec. 19	CI
Transcript : Anavex Life Sciences Corp., 2023 Earnings Call, Nov 27, 2023	Nov. 27
Anavex Life Sciences Corp. Reports Earnings Results for the Full Year Ended September 30, 2023	Nov. 27	CI
Anavex Life Sciences Corp. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	Nov. 27	CI
North American Morning Briefing : Stock Futures -2-	Nov. 27	DJ
MORNING BID AMERICAS-Stocks stall after VIX hits pre-COVID low	Nov. 27	RE
Anavex Life Sciences Secures New Patent for Insomnia, Anxiety Treatment	Nov. 22	MT
Anavex Life Sciences Begins European Marketing Authorization Process for Blarcamesine to Treat Alzheimer's Disease	Nov. 20	MT
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer?s Disease to European Medicines Agency	Nov. 20	CI
Anavex Life Sciences Corp. Appoints David Goldberger as Senior Vice President Regulatory Affairs	Nov. 06	CI
Anavex Life Sciences Corp. Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX(R) 3-71 to Prevent Cognitive Decline in Alzheimer's Disease	23-10-25	CI

Chart Anavex Life Sciences Corp.

Duration

Period

More charts

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimerâs disease, Parkinsonâs disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Companyâs product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.49 USD

Average target price

27.5 USD

Spread / Average Target

+512.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ANAVEX LIFE SCIENCES CORP.	-51.77%	380M
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	113B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
ARGENX SE	+0.87%	22.27B
BIONTECH SE	-12.64%	22.22B
GENMAB A/S	-5.48%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-8.58%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.77%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.52B

Bio Therapeutic Drugs